Venture Capital firm Asabys Partners closed its second fund, Sabadell Asabys Health Innovation Investments II, with total commitments of €180 million ($200 million). The funds will go towards 12 to 15 ...

The FDA has approved Cobenfy, a dual M1/M4 muscarinic agonist that offers a fundamentally different approach to treating ...

In one of the largest private rounds raised by an Italian biotech, Genespire Srl has closed a €46.6 million (US$51.88 million) series B, enabling it to lay the ground for a phase I/II clinical trial ...

Nine years on from securing $3.84 million for a phase I clinical trial to test the formulation, with results showing it ...

Mental tech startup Doctorpresso Co. Ltd. launched an audio journaling mobile application called Redi, in South Korea, as a voice analysis software capable of detecting depression through artificial ...

Neo Medical SA raised $68 million in a series B financing round to accelerate the growth of its spine surgical technologies in the U.S. The infusion of funds allows the company to deploy new products ...

Both chambers of the U.S. Congress put aside their election year politicking Sept. 25 long enough to pass a continuing ...

Neuros Medical Inc.’s Altius direct electrical nerve stimulation system significantly reduced pain in 30 minutes and ...

Researchers from Moderna Inc. and affiliated organizations presented preclinical data for the novel mRNA-lipid nanoparticle ...

Copyright ©2024. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing Cookie Settings ...

The FDA’s Oncologic Drugs Advisory Committee (ODAC) met for what chairperson Christopher Lieu called, at the end, “an incredibly long day” to decide whether approval of immune checkpoint inhibitors ...

The risk and benefit of Pfizer Inc.’s oral sickle cell disease drug Oxbryta (voxelotor) has flipped, prompted by what the company called new clinical data indicating “an imbalance in vaso-occlusive ...